10-Q: BiomX Inc. Reports First Quarter 2024 Results, Completes Acquisition of Adaptive Phage Therapeutics

BiomX Inc. reports a net loss of $17.3 million for the first quarter of 2024, alongside the completion of the Adaptive Phage Therapeutics acquisition and a $50 million private placement.

Summary

• BiomX Inc. reported a net loss of $17.3 million for the quarter ended March 31, 2024, compared to a net loss of $6.4 million for the same period in 2023.
• The company completed the acquisition of Adaptive Phage Therapeutics (APT) on March 15, 2024, which included the issuance of 9,164,968 shares of common stock, 40,470 redeemable convertible preferred shares, and warrants for 2,166,497 shares.
• Concurrently with the acquisition, BiomX closed a private placement (PIPE) raising approximately $50 million through the issuance of 216,417 redeemable convertible preferred shares and warrants for 108,208,500 shares.
• Research and development expenses decreased to $4.1 million from $4.6 million year-over-year, primarily due to the completion of enrollment in the BX004 clinical trial.
• General and administrative expenses increased to $2.7 million from $1.6 million year-over-year, mainly due to acquisition and PIPE related costs.
• The company prepaid its long-term debt of $10.4 million, including an end-of-term charge of $0.98 million.
• Basic and diluted loss per share was $0.28, compared to $0.20 in the same quarter of the previous year.
• As of March 31, 2024, BiomX had $44.1 million in cash and cash equivalents and restricted cash.
• The company believes its current funds will be sufficient to fund operations for at least one year from the issuance date of the financial statements.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the acquisition and PIPE are positive developments, the significant net loss and the need for future capital raises temper the overall sentiment. The company's future success is heavily dependent on the outcomes of its clinical trials and its ability to secure additional funding.

Positives

• The acquisition of APT significantly expands BiomX's pipeline with two Phase 2 assets.
• The $50 million PIPE provides substantial funding for ongoing and future operations.
• BX004 received Fast Track and Orphan Drug designations from the FDA, potentially accelerating its development.
• The company has a clear timeline for upcoming clinical trial readouts for both BX004 and BX211.
• The company has sufficient funds to operate for at least one year.

Negatives

• The company reported a significant net loss of $17.3 million for the quarter.
• General and administrative expenses increased substantially due to acquisition and PIPE related costs.
• The company's accumulated deficit has reached $180.3 million.
• The conversion of the preferred shares issued in the PIPE and acquisition is subject to stockholder approval, which is not guaranteed.
• The company has not generated revenue from operations and does not expect significant revenue in the next twelve months.

Risks

• The company's ability to raise additional capital is dependent on market demand and other factors.
• Failure to obtain stockholder approval for the conversion of preferred shares could require the company to redeem them at fair value.
• The ongoing war in Israel could potentially impact the company's business and operations.
• The company is subject to risks related to clinical trial outcomes, regulatory approvals, and competition.
• The company has incurred significant losses and negative cash flows from operations and expects to continue to do so.

Future Outlook

BiomX plans to continue focusing on the development of BX004 for cystic fibrosis and BX211 for diabetic foot osteomyelitis. The company expects to incur additional losses in the foreseeable future and will need to raise additional capital through various means. The company believes its current funds will be sufficient to fund operations for at least one year from the issuance date of these financial statements.

Management Comments

• Management believes that its available funds as of the issuance date of the financial statements will be sufficient to fund its operations for at least one year.
• Management acknowledges that the conversion of the preferred shares is subject to stockholder approval and is not guaranteed.

Industry Context

The announcement reflects the ongoing trend of biotech companies focusing on novel therapies, particularly in areas with unmet medical needs such as cystic fibrosis and diabetic foot osteomyelitis. The use of phage therapy is an emerging area in the treatment of bacterial infections, offering a potential alternative to traditional antibiotics.

Comparison to Industry Standards

• BiomX's focus on phage therapy aligns with the growing interest in alternative antimicrobial approaches, similar to companies like AmpliPhi Biosciences (now Armata Pharmaceuticals) and Intralytix, which also develop phage-based therapies.
• The company's Phase 2 clinical trials for BX004 and BX211 are comparable to other biotech companies in the clinical stage, such as Spero Therapeutics and Achaogen (now defunct), which have focused on developing novel antibiotics.
• The financial results, including the net loss and cash burn, are typical for a clinical-stage biotech company, similar to companies like Assembly Biosciences and Arcus Biosciences, which are also investing heavily in R&D.
• The $50 million PIPE is a common financing method for biotech companies, similar to recent financings by companies like Xencor and IGM Biosciences, which have raised capital to fund their clinical programs.

Stakeholder Impact

• Shareholders face increased risk due to the company's significant losses and the need for future capital raises.
• Employees may be impacted by the company's financial situation and the potential for future restructuring.
• Patients with cystic fibrosis and diabetic foot osteomyelitis may benefit from the company's ongoing clinical trials and the potential for new treatment options.
• Creditors may be impacted by the company's financial situation and its ability to repay its debts.

Next Steps

• Initiate a Phase 2b study for BX004 in cystic fibrosis patients in the fourth quarter of 2024.
• Continue the Phase 2 study for BX211 in diabetic foot osteomyelitis.
• Seek stockholder approval for the conversion of preferred shares issued in the PIPE and acquisition.
• Explore additional funding options to support ongoing operations and development activities.

Key Dates

Keywords

phage therapy, cystic fibrosis, diabetic foot osteomyelitis, bacteriophage, clinical trials, acquisition, private placement, BX004, BX211, FDA, research and development